Highlights pre|CISION® Platform Data

Avacta’s AVA6103 shows strong preclinical results, with key human data expected in 2027.

What the company is saying

Avacta Group plc is emphasizing the scientific progress of its pre|CISION® platform and the FAP-Exd (AVA6103) candidate, highlighting both preclinical superiority over Enhertu® and the ongoing advancement of the FOCUS-01 Phase 1 clinical trial. The company frames AVA6103 as a 'Next-Generation' controlled-release peptide-drug conjugate, designed for targeted delivery with a wider therapeutic window, and claims enhanced efficacy in animal models resistant to Enhertu®. The announcement stresses proof-of-mechanism, a favorable safety profile, and pharmacokinetic alignment between preclinical and early clinical data, with tolerability up to a payload dose approximately 50% higher than the maximum tolerated dose of conventional exatecan. Avacta’s Chief Medical Officer, Dave Liebowitz, and lead investigator Alexander Spira are cited to reinforce clinical credibility and the novelty of the mechanism. The company’s language is confident, focusing on the potential for improved outcomes in aggressive cancers, but does not provide financial or commercial projections. The release positions upcoming tumor PK and efficacy data as the next major milestones.

What the data suggests

Preclinical data demonstrate that AVA6103 achieved more than double the tumor growth inhibition of Enhertu® in early-stage animal models (tumors 100-200mm3), and maintained activity in larger, established tumors (400-500mm3) where Enhertu® had limited effect. All AVA6103-treated animals previously resistant to Enhertu® achieved stable disease, while those retreated with Enhertu® progressed. Safety and pharmacokinetic data from the first three dose levels of FOCUS-01 show tolerability up to a payload dose approximately 50% higher than the maximum tolerated dose of conventional exatecan, with dose level 4 reaching more than double the MTD. The pharmacokinetic profile in patients matches preclinical models, supporting the translation of preclinical efficacy to the clinic. No human efficacy data are yet available, and the most material clinical readouts (tumor PK and efficacy) are expected in late Q4 2026 or H1 2027. The claims of platform novelty and biological mechanism are not yet substantiated with quantitative human data.

Analysis

The announcement is upbeat, highlighting both preclinical superiority of AVA6103 over Enhertu® in animal models and ongoing progress in the FOCUS-01 Phase 1 clinical trial. The majority of claims are realised and supported by specific preclinical and early clinical data, such as tumor growth inhibition and dose escalation milestones. However, the most material clinical benefits (tumor PK and efficacy data) are not expected until late Q4 2026 or H1 2027, making the execution distance long-term. The language around 'first Next-Generation' and 'similar kinetics to ADCs' is promotional, as no direct comparative human data or kinetic measurements are disclosed. There is no mention of capital outlay or financial metrics, but as this is a clinical-stage biotech update, this is not a deficiency. The overall tone is proportionate to the scientific progress, but some claims about platform novelty and biological mechanisms are not fully substantiated with quantitative data.

Risk flags

• ●The primary risk is that preclinical superiority in animal models may not translate into clinical efficacy in humans, as many oncology candidates fail at this stage despite promising animal data.
• ●The absence of interim human efficacy data means that the investment case currently rests on preclinical and early safety signals, with no proof yet that AVA6103 will outperform existing therapies in patients.
• ●The timeline to key clinical data is several months away, increasing the risk of delays or negative surprises before value inflection.
• ●Claims of platform novelty and mechanism are not yet supported by quantitative human data, which could lead to disappointment if future results do not confirm the hypothesized advantages.
• ●No financial data, cash runway, or funding status is disclosed, leaving uncertainty about the company’s ability to fund operations through the next clinical milestones.

Bottom line

Avacta’s update provides detailed preclinical and early clinical safety data for AVA6103, showing strong tumor inhibition in animal models and tolerability at doses up to 50% higher than conventional exatecan. The company’s narrative is credible at the scientific level, but the lack of human efficacy data means the investment case is not yet de-risked. The next major catalysts—tumor PK and efficacy readouts—are expected in late Q4 2026 or H1 2027, so investors must wait several months for validation. The main risk is that animal model success does not guarantee human benefit, and no financial disclosures are provided to assess funding runway. The most important takeaway is that while AVA6103’s preclinical profile is promising, the real test will come with the first human efficacy data in 2027.

Announcement summary

(AIM:AVCT) Avacta Group plc announced the presentation of the FOCUS-01 Phase 1 clinical trial design and new preclinical data for its pre|CISION® platform and FAP-Exd (AVA6103) at the European Society for Medical Oncology (ESMO) Congress. AVA6103 is the first Next-Generation pre|CISION® controlled-release peptide-drug conjugate (PDC), a fibroblast activation protein (FAP)-activated exatecan (Exd) PDC, designed to deliver payload to tumors with similar kinetics to antibody drug conjugates (ADCs) using small molecule chemistry. Preclinical data showed that AVA6103 achieved superior disease control compared to Enhertu® in a patient-derived xenograft (PDX) mouse model with HER2+/FAP+ gastric tumors that had progressed after initial Enhertu® treatment, attributed to enhanced cleavage potential and recruitment of FAP+ fibroblasts during AVA6103 treatment. In early-stage models (tumors 100-200mm3), all AVA6103-treated animals achieved partial responses, with tumor growth inhibition more than double that of Enhertu®. In animals with large established tumors (400-500mm3), AVA6103 inhibited tumor growth and achieved partial responses, while Enhertu® showed limited activity. All AVA6103-treated animals previously progressed on Enhertu® achieved stable disease, while all animals retreated with Enhertu® progressed. Tumor tissue studies demonstrated increased FAP expression over time with AVA6103, and transcriptomic analysis revealed a coordinated inflammatory and wound-healing response. The FOCUS-01 Phase 1a trial is a first-in-human, multicenter dose escalation trial of AVA6103, enrolling patients with select tumor types predicted to be sensitive to exatecan based on co-expression of FAP and SLFN11. Preliminary safety and pharmacokinetic (PK) data from the first three dose levels, reported in September, demonstrated proof of mechanism, a favorable safety profile, and tolerability up to a payload dose approximately 50% higher than the maximum tolerated dose (MTD) of conventional exatecan. Enrollment is ongoing in both arms, with dose level 4 completed, representing an absolute payload dose more than double the MTD of conventional exatecan and approaching the equivalent topoisomerase I inhibitor payload dose of the approved Enhertu® dose in breast cancer. The FOCUS-01 trial is progressing towards tumor PK data in late Q4 2026 or early Q1 2027 and first efficacy data expected in H1 2027. The poster presentation at ESMO was authored by Alexander I. Spira, Nehal J. Lakhani, Judy S. Wang, Muhammad R. Khawaja, Ruairidh Edwards, Karen Campbell, Curtis Rink, Christiana Nikolova, and David Liebowitz. Dave Liebowitz is Chief Medical Officer of Avacta. Alexander Spira MD, PhD, FACP, FASCO is Lead author at ESMO, Co-Director, Virginia Cancer Specialists (VCS) Research Institute, and a lead investigator of the trial. Enhertu® (trastuzumab deruxtecan; T-DXd) is a protease cleavable-linker ADC approved for breast and gastric cancer indications and is a registered trademark of Daiichi Sankyo Company, Limited and AstraZeneca.

Disagree with this article?